Halozyme Therapeutics, Inc. (HALO) Fair Value 2026

HALO · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

10.0 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (5/100)

Quick Summary — As of 2026-07-13, Halozyme Therapeutics, Inc. (HALO) trades at $76.11, approximately 35% above CirclFi’s Bayesian DCF fair value of $56.26. QOC: 10.0/10. Value Trap Risk: 5/100 (SAFE). 12/13 models active.

Key Facts

Ticker
HALO
Price
$76.11
Quality Score
10.0/10
Value Trap Risk
5/100
Models Active
12/13
Last Updated
Strength: First Chicago suggests +0.9% upside with 59% confidence
Risk: Majority of models suggest overvaluation

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($76.11)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
 $56.26 -26.1%
Earnings Power Value
High Conviction
 $7.13 -90.6%
CUCE Ensemble
Low Conviction
 $52.03 -31.6%
First Chicago
High Conviction
 $76.82 +0.9%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Halozyme Therapeutics, Inc. (HALO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Halozyme Therapeutics, Inc.'s intrinsic value is estimated at $65.51. Trading at its current price of $76.11, the valuation engine raises significant caution: 9 of 12 models flag downside risk, projecting an average implied return of -13.9%. Notably, Markov DDM sees the most upside at +239.1% (fair value: $258.08), while ML-RIV is the most conservative at -93.8% ($4.75). The spread between these extremes — +332.9% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About HALO?

12 of 13 models are currently active for HALO. Of these, 3 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates HALO's intrinsic value at $56.26, implying -26.1% downside from the current price. See which stocks rank higher →

How Does HALO Rank in Biological Products, (No Diagnostic Substances)?

Among 139 Biological Products, (No Diagnostic Substances) stocks, HALO ranks #2 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places HALO in the top tier.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Halozyme Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is HALO a Value Trap?

CirclFi's Value Trap algorithm assigns HALO a score of 5/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Halozyme Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Halozyme Therapeutics, Inc. earns a quality score of 10.0/10. This exceptional rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +332.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HALO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HALO's 12 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Halozyme Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8VCELVericel CorporationQOC 7.6

Read investment analysis: EXEL · NBIX · GILD · PLX · BIIB

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Halozyme Therapeutics, Inc.

What is Halozyme Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Halozyme Therapeutics, Inc. (HALO) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $56.26. The Quality of Company score is 10.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HALO overvalued or undervalued right now?

At $76.11, 3 of 12 active models suggest HALO may be undervalued, while 9 indicate potential overvaluation. The assessment depends on which methodology best fits Halozyme Therapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 10.0 mean for HALO?

Halozyme Therapeutics, Inc.'s QOC of 10.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on HALO?

CirclFi analyzes HALO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is HALO a value trap in 2026?

Halozyme Therapeutics, Inc.'s Value Trap score is 5/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on HALO.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access